Unknown

Dataset Information

0

Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence.


ABSTRACT: Matrix metalloproteinase (MMP)-9 is crucial in atherosclerotic plaque rupture and tissue remodeling after a cardiac event. The balance between MMP-9 and endogenous inhibitor, tissue inhibitors of matrix metalloproteinase 1 (TIMP-1), is important in acute coronary syndrome (ACS). This is an age- and gender-matched case-control study of ACS (N = 669). Patients (45.7%) were resampled after recovery, and all were followed up for 6 years. The molecular forms of MMP-9 were investigated by gelatin zymography. Diagnostically, MMP-9 and the MMP-9/TIMP-1 molar ratio were associated with ACS (OR 5.81, 95% CI 2.65-12.76, and 4.96, 2.37-10.38). The MMP-9 concentrations decreased 49% during recovery (p < 0.001). The largest decrease of these biomarkers between acute and recovery phase (ΔMMP-9) protected the patients from major adverse cardiac events, especially the non-fatal events. The fatal events were associated with in vitro activatable MMP-9 levels (p = 0.028). Serum MMP-9 and the MMP-9/TIMP-1 molar ratio may be valuable in ACS diagnosis and prognosis. High serum MMP-9 activation potential is associated with poor cardiovascular outcome.

SUBMITTER: Lahdentausta L 

PROVIDER: S-EPMC5974001 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence.

Lahdentausta Laura L   Leskelä Jaakko J   Winkelmann Alina A   Tervahartiala Taina T   Sorsa Timo T   Pesonen Erkki E   Pussinen Pirkko J PJ  

Journal of cardiovascular translational research 20180118 3


Matrix metalloproteinase (MMP)-9 is crucial in atherosclerotic plaque rupture and tissue remodeling after a cardiac event. The balance between MMP-9 and endogenous inhibitor, tissue inhibitors of matrix metalloproteinase 1 (TIMP-1), is important in acute coronary syndrome (ACS). This is an age- and gender-matched case-control study of ACS (N = 669). Patients (45.7%) were resampled after recovery, and all were followed up for 6 years. The molecular forms of MMP-9 were investigated by gelatin zymo  ...[more]

Similar Datasets

| S-EPMC4609776 | biostudies-literature
| S-EPMC2987528 | biostudies-literature
| S-EPMC8867112 | biostudies-literature
| S-EPMC4054466 | biostudies-other
| S-EPMC3760575 | biostudies-literature
| S-EPMC5666874 | biostudies-literature
| S-EPMC8182505 | biostudies-literature
| S-EPMC8182988 | biostudies-literature
| S-EPMC10634147 | biostudies-literature
| S-EPMC7080940 | biostudies-literature